Background: Administration of terlipressin can reverse hypotension in potential organ donors with norepinephrine-resistance. The aim of this study was to determine the effects of terlipressin on the hemodynamics, liver function, and renal function of hypotensive brain-dead patients who were potential organ donors.Methods: A retrospective study was conducted by using the ICU database of one hospital. 18 patients in a total of 294 brain-dead cases were enrolled and administered terlipressin intravenously. All physiological parameters of recruited patients were obtained at baseline, 24 and 72 h after administration, and immediately before organ procurement.Results: Terlipressin induced significant increases in mean arterial pressure (MAP) from...
Abstract Background and Aim Hepatorenal syndrome (HRS) is a fatal complication of liver cirrhosis wi...
The treatment of choice for hepatorenal syndrome-acute kidney injury (HRS-AKI) is vasoconstrictor th...
Hepatorenal syndrome is a rapidly lethal complication of cirrhosis. The present case provides furthe...
Management of potential brain death organ donors (BDOD) requires strategies to manage severe cardio...
INTRODUCTION: We investigated whether treatment with terlipressin during recovery from hypotension d...
WOS: 000458370600019PubMed ID: 30729953Background: Patients with end-stage liver disease are prone t...
Hepatorenal syndrome (HRS) is a severe complication in patients with endstage liver disease. It con...
AIM OF STUDY: To report the management of cardiovascular failure refractory to standard catecholamin...
Abstract Introduction We investigated whether treatme...
International audienceINTRODUCTION: Circulatory failure during brain death organ donor resuscitation...
Background and Aim: Terlipressin is a vasopressin analog that may improve renal function in hepatore...
Background: Hepatorenal syndrome (HRS) is a severe complication of end-stage renal disease whose man...
Although terlipressin (TP) may improve renal function in cirrhotic patients, its use in sepsis remai...
The treatment of choice for hepatorenal syndrome-acute kidney injury (HRS-AKI) is vasoconstrictor th...
[[abstract]]Terlipressin, an analogue of vasopressin, is frequently used for the management of esoph...
Abstract Background and Aim Hepatorenal syndrome (HRS) is a fatal complication of liver cirrhosis wi...
The treatment of choice for hepatorenal syndrome-acute kidney injury (HRS-AKI) is vasoconstrictor th...
Hepatorenal syndrome is a rapidly lethal complication of cirrhosis. The present case provides furthe...
Management of potential brain death organ donors (BDOD) requires strategies to manage severe cardio...
INTRODUCTION: We investigated whether treatment with terlipressin during recovery from hypotension d...
WOS: 000458370600019PubMed ID: 30729953Background: Patients with end-stage liver disease are prone t...
Hepatorenal syndrome (HRS) is a severe complication in patients with endstage liver disease. It con...
AIM OF STUDY: To report the management of cardiovascular failure refractory to standard catecholamin...
Abstract Introduction We investigated whether treatme...
International audienceINTRODUCTION: Circulatory failure during brain death organ donor resuscitation...
Background and Aim: Terlipressin is a vasopressin analog that may improve renal function in hepatore...
Background: Hepatorenal syndrome (HRS) is a severe complication of end-stage renal disease whose man...
Although terlipressin (TP) may improve renal function in cirrhotic patients, its use in sepsis remai...
The treatment of choice for hepatorenal syndrome-acute kidney injury (HRS-AKI) is vasoconstrictor th...
[[abstract]]Terlipressin, an analogue of vasopressin, is frequently used for the management of esoph...
Abstract Background and Aim Hepatorenal syndrome (HRS) is a fatal complication of liver cirrhosis wi...
The treatment of choice for hepatorenal syndrome-acute kidney injury (HRS-AKI) is vasoconstrictor th...
Hepatorenal syndrome is a rapidly lethal complication of cirrhosis. The present case provides furthe...